BR9712824A - Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico - Google Patents

Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico

Info

Publication number
BR9712824A
BR9712824A BR9712824-4A BR9712824A BR9712824A BR 9712824 A BR9712824 A BR 9712824A BR 9712824 A BR9712824 A BR 9712824A BR 9712824 A BR9712824 A BR 9712824A
Authority
BR
Brazil
Prior art keywords
optic nerve
nerve disorder
functional optic
ophthalmic composition
treatment agent
Prior art date
Application number
BR9712824-4A
Other languages
English (en)
Inventor
Shinseiro Okamoto
Original Assignee
Advanced Medicine Research Ins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Research Ins filed Critical Advanced Medicine Research Ins
Publication of BR9712824A publication Critical patent/BR9712824A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção:<B>"COMPOSIçãO OFTáLMICA DE FATOR NEUROTRóFICO, AGENTE DE TRATAMENTO DE DESORDEM FUNCIONAL DO NERVO óTICO E MéTODO PARA TRATAMENTO DE DESORDEM FUNCIONAL DO NERVO óTICO"<D>. De acordo com a presente invenção, são fornecidos uma composição oftálmica que compreende um fator neurotrópico, uma agente de tratamento de desordem funcional do nervo ótico que compreende um fator neurotrópico, e um método para tratamento de uma desordem funcional do nervo ótico, que compreende administrar uma quantidade efetiva de um fator neurotrópico, particularmente um agente de tratamento de glaucoma e um método para tratamento do mesmo.
BR9712824-4A 1996-09-13 1997-09-12 Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico BR9712824A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24317996 1996-09-13
PCT/JP1997/003241 WO1998010785A1 (fr) 1996-09-13 1997-09-12 Compositions ophtalmiques de facteurs neurotrophiques, remedes pour troubles fonctionnels du nerf optique et procede de traitement de tels troubles

Publications (1)

Publication Number Publication Date
BR9712824A true BR9712824A (pt) 1999-12-21

Family

ID=17100001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712824-4A BR9712824A (pt) 1996-09-13 1997-09-12 Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico

Country Status (9)

Country Link
US (2) US6261545B1 (pt)
EP (1) EP0958831A4 (pt)
KR (1) KR100514277B1 (pt)
CN (1) CN1233963A (pt)
AU (1) AU743308B2 (pt)
BR (1) BR9712824A (pt)
CA (1) CA2265743A1 (pt)
IL (1) IL128941A (pt)
WO (1) WO1998010785A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
AU5109400A (en) * 1999-06-14 2001-01-02 Advanced Medicine Research Institute Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions
EA006220B1 (ru) * 1999-07-22 2005-10-27 Авентис Фармасьютиклс, Инк. Многодозовые эритропоэтиновые составы
AU2002313716A1 (en) * 2001-07-31 2003-02-17 University Of Medicine And Dentistry Of New Jersey Method of utilizing neurotrophins to manipulate reproductive capacity
IL164822A0 (en) * 2002-04-25 2005-12-18 Rapidheal Inc Growth factor delivery system for the healing of wounds and the prevention and disease
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
NZ607886A (en) 2003-03-19 2014-09-26 Biogen Idec Inc Nogo receptor binding protein
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050058730A1 (en) * 2003-09-15 2005-03-17 Xushan Wan Compositions and methods for preventing or treating eyestrain
US20060287246A1 (en) * 2003-09-24 2006-12-21 Shinji Yoneda Remedy for eye diseases accompanied by optic nerve injuries
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
WO2006040839A1 (ja) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute 眼疾患処置用点眼剤及びキット
JP2009502123A (ja) 2005-07-08 2009-01-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５抗体およびその使用
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
AU2006270041B2 (en) * 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
WO2007100382A2 (en) 2005-10-27 2007-09-07 Bernstein Lawrence R Orally administrable gallium compositions and method of use
US20070259021A1 (en) * 2006-05-01 2007-11-08 Friedlaender Mitchell H Compositions, Methods, and Kits for Treating Dry Eye
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
US20090156587A1 (en) * 2007-12-12 2009-06-18 Ravi Nallakrishnan Eye Medication Formulation with Antibacterial Agent
EP2982695B1 (en) 2008-07-09 2019-04-03 Biogen MA Inc. Compositions comprising antibodies to lingo or fragments thereof
IT1396607B1 (it) * 2009-11-16 2012-12-14 Hmfra Hungary Ltd Liability Company Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso.
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
CA2884598A1 (en) 2012-08-10 2014-02-13 Osio Corporation d/b/a Yolia Health Contact lens use in the treatment of an ophthalmologic condition
EP3074050B1 (en) * 2013-10-28 2020-09-09 Icahn School of Medicine at Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
CN103656621A (zh) * 2013-12-02 2014-03-26 黄丽娜 一种新型鼠神经生长因子玻璃体腔注射给药系统及其应用
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN109477002A (zh) 2016-07-28 2019-03-15 国际壳牌研究有限公司 从固体生物质生产富含芳香烃的高级烃
IT201700066486A1 (it) * 2017-06-15 2018-12-15 Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
US20210275638A1 (en) * 2020-03-04 2021-09-09 The Schepens Eye Research Institute, Inc. Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
CN111705069A (zh) * 2020-06-19 2020-09-25 武汉纽福斯生物科技有限公司 一种多神经营养因子联合表达载体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203440A (en) 1981-06-11 1982-12-13 Nihon Contact Lens Seizou Kk Treating tool
CA1295941C (en) * 1985-08-16 1992-02-18 Rajan Bawa Sustained-release formulation comprising a hydrophobic polymer system
AU615637B2 (en) * 1986-10-17 1991-10-10 Surmodics, Inc. Improvement of the biocompatibility of solid surfaces
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US5667968A (en) 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
CA2036606A1 (en) * 1990-02-20 1991-08-21 Michael Colvin Coated intraocular lens and coatings therefor
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
EP0671879B1 (en) * 1992-02-14 2000-05-24 Regeneron Pharmaceuticals, Inc. Prevention of injury and degeneration of photoreceptors by neurotrophic factors
EP0644937A4 (en) * 1992-06-12 1995-05-03 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression.
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
WO1995026363A1 (en) 1994-03-29 1995-10-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Neurotrophin-6: a new member of the neurotrophin family
US5898066A (en) 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤

Also Published As

Publication number Publication date
AU4220997A (en) 1998-04-02
CN1233963A (zh) 1999-11-03
EP0958831A1 (en) 1999-11-24
US6261545B1 (en) 2001-07-17
KR100514277B1 (ko) 2005-09-13
EP0958831A4 (en) 2004-04-07
IL128941A0 (en) 2000-02-17
WO1998010785A1 (fr) 1998-03-19
US20010023245A1 (en) 2001-09-20
IL128941A (en) 2007-05-15
KR20000036116A (ko) 2000-06-26
AU743308B2 (en) 2002-01-24
CA2265743A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
BR9712824A (pt) Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
BR9914109A (pt) Composições antibióticas para tratamento dos olhos, ouvidos e nariz
DK1075265T3 (da) Anvendelse af tetracycliner til behandling af sygdom i de Meibomske kirtler
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
BR9913156A (pt) Composição e processo para condicionamento, clareamento e realce do cabelo
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0211011A (pt) Composição, método para fornecimento de estabilidade fìsica, método para tratamento de fibras queratìnicas e kit de múltiplos compartimentos
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
BR9911887A (pt) Método para o tratamento da insÈnia
DE69939956D1 (de) Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten Harninkontinenz
BR9914158A (pt) Composição antibiótica para o tratamento dos olhos, ouvidos e nariz
KR960033452A (ko) 시신경 질환의 치료를 위한 프로스타노산 화합물
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.